APO Research
Talk to an analyst

APO RESEARCH · REPORT

Short-acting B2 Agonists

Compare research editions
View pricing & licenses

Selected research

Industry Research

Short-acting B2 Agonists Industry Research Report 2026

20 December 2025116 pages

Choose your research edition.

Industry ResearchShort-acting B2 Agonists Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Short-acting B2 Agonists Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Short-acting B2 Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Short-acting B2 Agonists Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Short-acting B2 Agonists Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Short-acting B2 Agonists market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Short-acting B2 Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Short-acting B2 Agonists is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Short-acting B2 Agonists is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Short-acting B2 Agonists include Teva, Johnson & Johnson, Merck, Roche, GSK, Bayer AG, Viatris and Cipla Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Short-acting B2 Agonists market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Short-acting B2 Agonists Market by Company

Teva

Johnson & Johnson

Merck

Roche

GSK

Bayer AG

Viatris

Cipla Limited

Short-acting B2 Agonists Segment by Type

Levalbuterol

Albuterol

Metaproterenol

Other

Short-acting B2 Agonists Segment by Application

COPD

Asthma

Other

Short-acting B2 Agonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Short-acting B2 Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Short-acting B2 Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Short-acting B2 Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Short-acting B2 Agonists manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Short-acting B2 Agonists by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Short-acting B2 Agonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Short-acting B2 Agonists Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Short-acting B2 Agonists Sales (k units) of Manufacturers (2021-2026) Table 7. Global Short-acting B2 Agonists Sales Market Share by Manufacturers (2021-2026) Table 8. Global Short-acting B2 Agonists Revenue of Manufacturers (2021-2026) Table 9. Global Short-acting B2 Agonists Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Short-acting B2 Agonists Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Short-acting B2 Agonists Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Short-acting B2 Agonists, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Short-acting B2 Agonists, Product Type & Application Table 14. Global Short-acting B2 Agonists Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Short-acting B2 Agonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Teva Company Information Table 19. Teva Business Overview Table 20. Teva Short-acting B2 Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Teva Short-acting B2 Agonists Product Portfolio Table 22. Teva Recent Developments Table 23. Johnson & Johnson Company Information Table 24. Johnson & Johnson Business Overview Table 25. Johnson & Johnson Short-acting B2 Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Johnson & Johnson Short-acting B2 Agonists Product Portfolio Table 27. Johnson & Johnson Recent Developments Table 28. Merck Company Information Table 29. Merck Business Overview Table 30. Merck Short-acting B2 Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Merck Short-acting B2 Agonists Product Portfolio Table 32. Merck Recent Developments Table 33. Roche Company Information Table 34. Roche Business Overview Table 35. Roche Short-acting B2 Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Roche Short-acting B2 Agonists Product Portfolio Table 37. Roche Recent Developments Table 38. GSK Company Information Table 39. GSK Business Overview Table 40. GSK Short-acting B2 Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. GSK Short-acting B2 Agonists Product Portfolio Table 42. GSK Recent Developments Table 43. Bayer AG Company Information Table 44. Bayer AG Business Overview Table 45. Bayer AG Short-acting B2 Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Bayer AG Short-acting B2 Agonists Product Portfolio Table 47. Bayer AG Recent Developments Table 48. Viatris Company Information Table 49. Viatris Business Overview Table 50. Viatris Short-acting B2 Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Viatris Short-acting B2 Agonists Product Portfolio Table 52. Viatris Recent Developments Table 53. Cipla Limited Company Information Table 54. Cipla Limited Business Overview Table 55. Cipla Limited Short-acting B2 Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Cipla Limited Short-acting B2 Agonists Product Portfolio Table 57. Cipla Limited Recent Developments Table 58. Global Short-acting B2 Agonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 59. Global Short-acting B2 Agonists Sales by Region (2021-2026) & (k units) Table 60. Global Short-acting B2 Agonists Sales Market Share by Region (2021-2026) Table 61. Global Short-acting B2 Agonists Sales by Region (2027-2032) & (k units) Table 62. Global Short-acting B2 Agonists Sales Market Share by Region (2027-2032) Table 63. Global Short-acting B2 Agonists Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Short-acting B2 Agonists Revenue Market Share by Region (2021-2026) Table 65. Global Short-acting B2 Agonists Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Short-acting B2 Agonists Revenue Market Share by Region (2027-2032) Table 67. North America Short-acting B2 Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. North America Short-acting B2 Agonists Sales by Country (2021-2026) & (k units) Table 69. North America Short-acting B2 Agonists Sales by Country (2027-2032) & (k units) Table 70. North America Short-acting B2 Agonists Revenue by Country (2021-2026) & (US$ Million) Table 71. North America Short-acting B2 Agonists Revenue by Country (2027-2032) & (US$ Million) Table 72. Europe Short-acting B2 Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. Europe Short-acting B2 Agonists Sales by Country (2021-2026) & (k units) Table 74. Europe Short-acting B2 Agonists Sales by Country (2027-2032) & (k units) Table 75. Europe Short-acting B2 Agonists Revenue by Country (2021-2026) & (US$ Million) Table 76. Europe Short-acting B2 Agonists Revenue by Country (2027-2032) & (US$ Million) Table 77. Asia Pacific Short-acting B2 Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Asia Pacific Short-acting B2 Agonists Sales by Country (2021-2026) & (k units) Table 79. Asia Pacific Short-acting B2 Agonists Sales by Country (2027-2032) & (k units) Table 80. Asia Pacific Short-acting B2 Agonists Revenue by Country (2021-2026) & (US$ Million) Table 81. Asia Pacific Short-acting B2 Agonists Revenue by Country (2027-2032) & (US$ Million) Table 82. South America Short-acting B2 Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. South America Short-acting B2 Agonists Sales by Country (2021-2026) & (k units) Table 84. South America Short-acting B2 Agonists Sales by Country (2027-2032) & (k units) Table 85. South America Short-acting B2 Agonists Revenue by Country (2021-2026) & (US$ Million) Table 86. South America Short-acting B2 Agonists Revenue by Country (2027-2032) & (US$ Million) Table 87. Middle East and Africa Short-acting B2 Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Middle East and Africa Short-acting B2 Agonists Sales by Country (2021-2026) & (k units) Table 89. Middle East and Africa Short-acting B2 Agonists Sales by Country (2027-2032) & (k units) Table 90. Middle East and Africa Short-acting B2 Agonists Revenue by Country (2021-2026) & (US$ Million) Table 91. Middle East and Africa Short-acting B2 Agonists Revenue by Country (2027-2032) & (US$ Million) Table 92. Global Short-acting B2 Agonists Sales by Type (2021-2026) & (k units) Table 93. Global Short-acting B2 Agonists Sales by Type (2027-2032) & (k units) Table 94. Global Short-acting B2 Agonists Sales Market Share by Type (2021-2026) Table 95. Global Short-acting B2 Agonists Sales Market Share by Type (2027-2032) Table 96. Global Short-acting B2 Agonists Revenue by Type (2021-2026) & (US$ Million) Table 97. Global Short-acting B2 Agonists Revenue by Type (2027-2032) & (US$ Million) Table 98. Global Short-acting B2 Agonists Revenue Market Share by Type (2021-2026) Table 99. Global Short-acting B2 Agonists Revenue Market Share by Type (2027-2032) Table 100. Global Short-acting B2 Agonists Price by Type (2021-2026) & (US$/unit) Table 101. Global Short-acting B2 Agonists Price by Type (2027-2032) & (US$/unit) Table 102. Global Short-acting B2 Agonists Sales by Application (2021-2026) & (k units) Table 103. Global Short-acting B2 Agonists Sales by Application (2027-2032) & (k units) Table 104. Global Short-acting B2 Agonists Sales Market Share by Application (2021-2026) Table 105. Global Short-acting B2 Agonists Sales Market Share by Application (2027-2032) Table 106. Global Short-acting B2 Agonists Revenue by Application (2021-2026) & (US$ Million) Table 107. Global Short-acting B2 Agonists Revenue by Application (2027-2032) & (US$ Million) Table 108. Global Short-acting B2 Agonists Revenue Market Share by Application (2021-2026) Table 109. Global Short-acting B2 Agonists Revenue Market Share by Application (2027-2032) Table 110. Global Short-acting B2 Agonists Price by Application (2021-2026) & (US$/unit) Table 111. Global Short-acting B2 Agonists Price by Application (2027-2032) & (US$/unit) Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Short-acting B2 Agonists Distributors List Table 115. Short-acting B2 Agonists Customers List Table 116. Short-acting B2 Agonists Industry Trends Table 117. Short-acting B2 Agonists Industry Drivers Table 118. Short-acting B2 Agonists Industry Restraints Table 119. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Short-acting B2 Agonists Product Image Figure 5. Global Short-acting B2 Agonists Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Short-acting B2 Agonists Market Size (2021-2032) & (US$ Million) Figure 7. Global Short-acting B2 Agonists Sales (2021-2032) & (k units) Figure 8. Global Short-acting B2 Agonists Average Price (US$/unit) & (2021-2032) Figure 9. Levalbuterol Product Image Figure 10. Albuterol Product Image Figure 11. Metaproterenol Product Image Figure 12. Other Product Image Figure 13. COPD Product Image Figure 14. Asthma Product Image Figure 15. Other Product Image Figure 16. Global Short-acting B2 Agonists Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Short-acting B2 Agonists, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Short-acting B2 Agonists Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Short-acting B2 Agonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Short-acting B2 Agonists Sales by Region in 2025 Figure 22. Global Short-acting B2 Agonists Revenue by Region in 2025 Figure 23. North America Short-acting B2 Agonists Market Size by Country in 2025 Figure 24. North America Short-acting B2 Agonists Sales Market Share by Country (2021-2032) Figure 25. North America Short-acting B2 Agonists Revenue Market Share by Country (2021-2032) Figure 26. United States Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Short-acting B2 Agonists Market Size by Country in 2025 Figure 30. Europe Short-acting B2 Agonists Sales Market Share by Country (2021-2032) Figure 31. Europe Short-acting B2 Agonists Revenue Market Share by Country (2021-2032) Figure 32. Germany Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Short-acting B2 Agonists Market Size by Country in 2025 Figure 43. Asia Pacific Short-acting B2 Agonists Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Short-acting B2 Agonists Revenue Market Share by Country (2021-2032) Figure 45. China Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Short-acting B2 Agonists Market Size by Country in 2025 Figure 54. South America Short-acting B2 Agonists Sales Market Share by Country (2021-2032) Figure 55. South America Short-acting B2 Agonists Revenue Market Share by Country (2021-2032) Figure 56. Brazil Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Short-acting B2 Agonists Market Size by Country in 2025 Figure 60. Middle East and Africa Short-acting B2 Agonists Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Short-acting B2 Agonists Revenue Market Share by Country (2021-2032) Figure 62. Egypt Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Short-acting B2 Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Short-acting B2 Agonists Sales Market Share by Type (2021-2032) Figure 68. Global Short-acting B2 Agonists Revenue Market Share by Type (2021-2032) Figure 69. Global Short-acting B2 Agonists Price (US$/unit) by Type (2021-2032) Figure 70. Global Short-acting B2 Agonists Sales Market Share by Application (2021-2032) Figure 71. Global Short-acting B2 Agonists Revenue Market Share by Application (2021-2032) Figure 72. Global Short-acting B2 Agonists Price (US$/unit) by Application (2021-2032) Figure 73. Short-acting B2 Agonists Value Chain Figure 74. Short-acting B2 Agonists Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Short-acting B2 Agonists Industry Opportunities and Challenges

Scope & coverage.

Types
  • Levalbuterol
  • Albuterol
  • Metaproterenol
  • Other
Applications
  • COPD
  • Asthma
  • Other
Companies covered
  • Teva
  • Johnson & Johnson
  • Merck
  • Roche
  • GSK
  • Bayer AG
  • Viatris
  • Cipla Limited

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Short-acting B2 Agonists Market Size (2021-2032)
  4. 2.2.2 Global Short-acting B2 Agonists Sales (2021-2032)
  5. 2.2.3 Global Short-acting B2 Agonists Market Average Price (2021-2032)
  6. 2.3 Short-acting B2 Agonists by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Levalbuterol
  9. 2.3.3 Albuterol
  10. 2.3.4 Metaproterenol
  11. 2.3.5 Other
  12. 2.4 Short-acting B2 Agonists by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 COPD
  15. 2.4.3 Asthma
  16. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Short-acting B2 Agonists Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Short-acting B2 Agonists Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Short-acting B2 Agonists Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Short-acting B2 Agonists Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Short-acting B2 Agonists Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Short-acting B2 Agonists, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Short-acting B2 Agonists, Product Type & Application
  8. 3.8 Global Manufacturers of Short-acting B2 Agonists, Established Date
  9. 3.9 Global Short-acting B2 Agonists Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva
  2. 4.1.1 Teva Company Information
  3. 4.1.2 Teva Business Overview
  4. 4.1.3 Teva Short-acting B2 Agonists Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Teva Short-acting B2 Agonists Product Portfolio
  6. 4.1.5 Teva Recent Developments
  7. 4.2 Johnson & Johnson
  8. 4.2.1 Johnson & Johnson Company Information
  9. 4.2.2 Johnson & Johnson Business Overview
  10. 4.2.3 Johnson & Johnson Short-acting B2 Agonists Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Johnson & Johnson Short-acting B2 Agonists Product Portfolio
  12. 4.2.5 Johnson & Johnson Recent Developments
  13. 4.3 Merck
  14. 4.3.1 Merck Company Information
  15. 4.3.2 Merck Business Overview
  16. 4.3.3 Merck Short-acting B2 Agonists Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Merck Short-acting B2 Agonists Product Portfolio
  18. 4.3.5 Merck Recent Developments
  19. 4.4 Roche
  20. 4.4.1 Roche Company Information
  21. 4.4.2 Roche Business Overview
  22. 4.4.3 Roche Short-acting B2 Agonists Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Roche Short-acting B2 Agonists Product Portfolio
  24. 4.4.5 Roche Recent Developments
  25. 4.5 GSK
  26. 4.5.1 GSK Company Information
  27. 4.5.2 GSK Business Overview
  28. 4.5.3 GSK Short-acting B2 Agonists Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 GSK Short-acting B2 Agonists Product Portfolio
  30. 4.5.5 GSK Recent Developments
  31. 4.6 Bayer AG
  32. 4.6.1 Bayer AG Company Information
  33. 4.6.2 Bayer AG Business Overview
  34. 4.6.3 Bayer AG Short-acting B2 Agonists Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Bayer AG Short-acting B2 Agonists Product Portfolio
  36. 4.6.5 Bayer AG Recent Developments
  37. 4.7 Viatris
  38. 4.7.1 Viatris Company Information
  39. 4.7.2 Viatris Business Overview
  40. 4.7.3 Viatris Short-acting B2 Agonists Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Viatris Short-acting B2 Agonists Product Portfolio
  42. 4.7.5 Viatris Recent Developments
  43. 4.8 Cipla Limited
  44. 4.8.1 Cipla Limited Company Information
  45. 4.8.2 Cipla Limited Business Overview
  46. 4.8.3 Cipla Limited Short-acting B2 Agonists Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Cipla Limited Short-acting B2 Agonists Product Portfolio
  48. 4.8.5 Cipla Limited Recent Developments
5 Global Short-acting B2 Agonists Market Scenario by Region
  1. 5.1 Global Short-acting B2 Agonists Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Short-acting B2 Agonists Sales by Region: 2021-2032
  3. 5.2.1 Global Short-acting B2 Agonists Sales by Region: 2021-2026
  4. 5.2.2 Global Short-acting B2 Agonists Sales by Region: 2027-2032
  5. 5.3 Global Short-acting B2 Agonists Revenue by Region: 2021-2032
  6. 5.3.1 Global Short-acting B2 Agonists Revenue by Region: 2021-2026
  7. 5.3.2 Global Short-acting B2 Agonists Revenue by Region: 2027-2032
  8. 5.4 North America Short-acting B2 Agonists Market Facts & Figures by Country
  9. 5.4.1 North America Short-acting B2 Agonists Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Short-acting B2 Agonists Sales by Country (2021-2032)
  11. 5.4.3 North America Short-acting B2 Agonists Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Short-acting B2 Agonists Market Facts & Figures by Country
  16. 5.5.1 Europe Short-acting B2 Agonists Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Short-acting B2 Agonists Sales by Country (2021-2032)
  18. 5.5.3 Europe Short-acting B2 Agonists Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Short-acting B2 Agonists Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Short-acting B2 Agonists Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Short-acting B2 Agonists Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Short-acting B2 Agonists Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Short-acting B2 Agonists Market Facts & Figures by Country
  41. 5.7.1 South America Short-acting B2 Agonists Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Short-acting B2 Agonists Sales by Country (2021-2032)
  43. 5.7.3 South America Short-acting B2 Agonists Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Short-acting B2 Agonists Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Short-acting B2 Agonists Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Short-acting B2 Agonists Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Short-acting B2 Agonists Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Short-acting B2 Agonists Sales by Type (2021-2032)
  2. 6.1.1 Global Short-acting B2 Agonists Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Short-acting B2 Agonists Sales Market Share by Type (2021-2032)
  4. 6.2 Global Short-acting B2 Agonists Revenue by Type (2021-2032)
  5. 6.2.1 Global Short-acting B2 Agonists Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Short-acting B2 Agonists Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Short-acting B2 Agonists Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Short-acting B2 Agonists Sales by Application (2021-2032)
  2. 7.1.1 Global Short-acting B2 Agonists Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Short-acting B2 Agonists Sales Market Share by Application (2021-2032)
  4. 7.2 Global Short-acting B2 Agonists Revenue by Application (2021-2032)
  5. 7.2.1 Global Short-acting B2 Agonists Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Short-acting B2 Agonists Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Short-acting B2 Agonists Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Short-acting B2 Agonists Value Chain Analysis
  2. 8.1.1 Short-acting B2 Agonists Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Short-acting B2 Agonists Production Mode & Process
  5. 8.2 Short-acting B2 Agonists Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Short-acting B2 Agonists Distributors
  8. 8.2.3 Short-acting B2 Agonists Customers
9 Global Short-acting B2 Agonists Analyzing Market Dynamics
  1. 9.1 Short-acting B2 Agonists Industry Trends
  2. 9.2 Short-acting B2 Agonists Industry Drivers
  3. 9.3 Short-acting B2 Agonists Industry Opportunities and Challenges
  4. 9.4 Short-acting B2 Agonists Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst